Endexx Contributes to Diabetic Neuropathy Case Study
CAVE CREEK, AZ–(Marketwired – Dec 9, 2014) – Endexx Corporation (OTC PINK: EDXC) announced today that it is providing its CBD (Cannabidiol) starter kit (M3Vape) to a voluntary patient study utilizing industrial hemp oil that is rich in CBD/CBDa, as an application to potentially alleviate symptoms arising from diabetic neuropathy. Thirteen diabetic patients suffering from neuropathy in Missouri began a 30 day voluntary study in late November under the oversight of Dr. Daniel Kiddy, DPM. Dr. Kiddy stated, “The main objective for this short study is to simply see if pain is decreased or eliminated. We are also monitoring if the proprioception and sharp and dull sensation are improved.”
Endexx’s “Cannsumable” Division is developing two primary product lines derived from food grade and lab-tested industrial hemp oil. The oil is naturally rich in both CBD and CBDa phytocannabinoids. The industrial hemp is grown on a certified eco-farm under organic farming practices. The oil is extracted utilizing critical CO2 extraction processes. The oil is tested both at the manufacturing site and in the United States at a certified lab. The product has no heavy metals, pesticides, or other contaminants and is tested using microbiological methods for determining mold and bacteria levels.
Endexx is researching the highest quality sources of industrial hemp oil that achieves the following primary goals:
(i) The product must be safe.
(ii) The product must be legal under federal law.
(iii) The product must provide maximum bioavailability.
(iv) The product must be beneficial to the patient/consumer.
Consumer and patient safety is Endexx’s foremost concern.
This study is not an official clinical trial. The study will provide general feedback from patients anecdotally, providing information to the doctors, patients and providers of the product. Public awareness of cannabis and industrial hemp products containing therapeutic and wellness properties has escalated over the past few years, yet education and research is limited. Understanding the benefits and the negatives of any supplement or nutraceutical is critical when determining the direction of a product’s development and future use by the medical community and/or the general adult population.
Endexx provides innovative medical marijuana management and technology solutions. The company has two technology products that launched in 2014 — the M3hub and the Autospense. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub database is the first standardized software platform for tracking pharmaceutical grade marijuana to support a Centralized Medical Marijuana Industry Repository and maintain compliance with the laws of State government and local regulatory bodies, as well as, provide a smooth transition to the eventual Federal mandates. The AutospenseTM is a high-tech marijuana inventory control and dispensing machine, which provides up to the minute accounting details and protects the security of the product as well as the patient. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Additionally, Endexx with its collaboration partners and consultants are developing two consumable product lines derived from industrial hemp that is organic and naturally rich in phytocannabinoids. Websites are: www.endexx.com,www.m3hub.com, www.autospense.com
Safe Harbor Notice
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
Chairman & CEO
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com